First Eagle Investment Management
CUE icon

First Eagle Investment Management’s Cue Biopharma CUE Stock Holding History

First Eagle Investment Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,500
Closed -$2.31M – 177
2018
Q2 		$2.31M Sell
6,500
-10,167
-61% -$4.04M 0.01% 152
2018
Q1 		$7.03M Buy
+16,667
New +$7.6M 0.02% 131

Other funds holding CUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management's CUE Position: Q3 2018 in Review

First Eagle Investment Management sold out of Cue Biopharma (CUE) in Q3 2018, closing a stake of 6,500 shares — an estimated $2.31M sold.

First Eagle Investment Management first reported a position in CUE in Q1 2018 and held it in 2 quarters. The position peaked at $7.03M in Q1 2018. 37 funds tracked by Wall St. Rank hold CUE as of Q3 2018.

  • First Eagle Investment Management reported no remaining Cue Biopharma position as of Q3 2018 after selling out during the quarter.
  • First Eagle Investment Management sold 6,500 Cue Biopharma shares in Q3 2018, an estimated $2.31M.
  • First Eagle Investment Management first reported a position in Cue Biopharma in Q1 2018 and held it in 2 quarters.
  • First Eagle Investment Management's Cue Biopharma position peaked at $7.03M in Q1 2018.
  • 37 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2018.

Based on First Eagle Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.